Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents - Monitor Patents Logo icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents

USPTO Class 530  |  Browse by Industry: Previous - Next | All     monitor keywords
Recent  |  14:  |  |  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
01/15/2015 > 21 patent applications in 15 patent subcategories.

20150018516 - Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer: Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (P2PDox) with antibodies or antigen-binding fragments thereof (ADCs), with targetable construct peptides or with other targeting molecules that are capable of delivering the P2PDox to a targeted cell, tissue or pathogen. Once delivered to the target cell,... Agent:

20150018517 - Fluorescent imaging agents: Provided is a family of intramolecularly quenched imaging agents for use in both in vivo and in vitro imaging that contain at least one enzymatically cleavable oligopeptide and two fluorophores or a fluorophore and a quencher. When subjected to proteolytic cleavage, at least one fluorophore is unquenched and becomes capable... Agent:

20150018518 - Ghrelin analogues: The present invention relates, inter alia, to ghrelin analogues and their medical use, for example in the treatment of cachexia, chronic obstructive pulmonary disease, gastrointestinal disorders (e.g., gastroparesis and/or inflammatory disorders such as colitis, gut barrier dysfunction, and ischemia reperfusion injury), loss of body weight, and decreased appetite.... Agent: Zealand Pharma A/s

20150018519 - Peptide c alpha-amides, methods for preparing same and uses thereof as precursors of peptide c alpha- thioesters for protein synthesis: The subject matter of the present invention is peptide Cα-amides which are precursors of peptide Cα-thioesters, characterized in that they comprise the radical of general formula (I) in which X, R1, R2, R3, R4, R5, R6, R7, R8, R9, n and A are as defined in Claim 1. The subject... Agent:

20150018520 - Inhibitors targeting human ghrelin o-acyltransferase: Grhelin O-acyltransferase inhibitors using a triazole linkage to incorporate aromatic and alkyl substituents to mimic the natural octanoyl group attached to ghrelin. Inhibitors include a triazole portion, an alkyl linker, and a hydrophobic aromatic group on a side chain. The hydrophobic aromatic group may include various length alkyl linkers.... Agent: Syracuse University

20150018522 - Catalytic domains of beta(1,4)-galactosyltransferase i having altered metal ion specificity: Disclosed are mutants of galactosyltransferases that can catalyze formation of oligosaccharides in the presence of magnesium; mutants of galactosyltransferases having altered donor and acceptor specificity which can catalyze formation of oligosaccharides in the presence of magnesium; methods and compositions that can be used to synthesize oligosaccharides; methods for increasing the... Agent: The United States Of America, As Represented By The Secretary, Department Of Health & Human Servic

20150018521 - Endoplasmic reticulum localization signals: The invention relates to cellular localization signals. In particular, the invention relates to endoplasmic reticulum localization signals in monomeric or multimeric form. The localization signals are utilized as research tools or are linked to therapeutics. Disclosed are methods of making and using polypeptides and modified polypeptides as signals to localize... Agent: Intrexon Corporation

20150018523 - Unnatural reactive amino acid genetic code additions: This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic... Agent:

20150018524 - Wound screen: A binding screen comprising a gas-porous solid non-water-dispersible carrier, to which has been substantially irreversibly bound a compound having matrix metalloproteinase binding functionality, particularly doxycycline.... Agent:

20150018525 - Method of producing recombinant high molecular weight vwf in cell culture: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with... Agent:

20150018528 - Antibodies that bind peptidoglycan recognition protein 1: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may... Agent:

20150018526 - Cytotoxins comprising modified bouganin toxin for the treatment of cancer: The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate... Agent: Merck Patent Gmbh

20150018527 - Methods and materials for assessing loss of heterozygosity: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying... Agent:

20150018530 - Novel prodrug containing molecule compositions and their uses: Novel prodrug compositions and uses thereof are provided.... Agent: Ambrx, Inc.

20150018529 - Sequence symmetric modified igg4 bispecific antibodies: The present disclosure relates to a symmetric bispecific antibody of the class IgG4 comprising two heavy chains which each comprise a variable domain, CH1 domain and a hinge region, wherein in each heavy chain: the cysteine in the CH1 domain which forms an inter-chain disulphide bond with a cysteine in... Agent:

20150018531 - Anti sez6 antibodies and methods of use: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.... Agent: Stem Centrx, Inc.

20150018532 - Antibody: The invention relates to antibodies to Aspergillus species and to methods of producing those antibodies. The invention also relates to the use of such antibodies in identifying the presence of the Aspergillus species and to methods of treating an infection with the Aspergillus species.... Agent: University Of Exeter

20150018534 - Antibody-immobilized carrier, method of producing antibody-immobilized carrier, and use of said antibody-immobilized carrier: The present invention provides an antibody-immobilized carrier that can be used in antibody screening, a method of producing the antibody-immobilized carrier, and use of the antibody-immobilized carrier. Efficient antibody screening can be carried out particularly by an antibody-immobilized carrier including two or more antibody immobilized regions onto each of which... Agent:

20150018533 - Repebody against immunoglobulin g and uses thereof: The present invention relates to a polypeptide (repebody) selectively bound to an immunoglobulin G, a polynucleotide which encodes the repebody, a vector containing the polynucleotide, a recombinant microorganism in which the polynucleotide is introduced, a method for producing the repebody using the recombinant microorganism, and a method for immobilizing or... Agent:

20150018535 - Glycoprotein enriched composition as a food and/or feed additive and/or as a therapeutic agent: The present invention relates to glycoprotein enriched compositions and their use in the treatment and/or prevention of disease, more particular gastro-intestinal diseases. The present invention further relates to the use of a glycoprotein enriched composition as a food or feed additive.... Agent:

20150018536 - Method for processing of carbon dioxide contained in an exhaust gas flow: A method for processing carbon dioxide contained in an exhaust gas flow. The exhaust gas flow is brought in contact in a drying and cooling chamber with a moistened porous silicate material and admixed aluminum hydroxide and/or hydrated aluminum oxide and/or optionally other metal oxidizers to produce a basic aqueous... Agent: Commerzialbank Matterburg Im Burgenland Aktiengesellschaft

01/08/2015 > 10 patent applications in 10 patent subcategories.

20150011728 - Reversibly crosslinked helical hydrogen bond surrogate macrocycles: The present invention relates to peptides having one or more stable, reversibly and internally-constrained HBS α-helices.... Agent: New York University

20150011729 - Nucleotide repeat expansion-associated polypeptides and uses thereof: Isolated polypeptides that are endogenously expressed from nucleotide repeat expansions are disclosed. In some cases, the polypeptides include polypeptide repeats. In some cases, the polypeptide repeats include at least five contiguous repeats of a single amino acid. In other cases, the repeats include at least six contiguous amino acids of... Agent:

20150011730 - Cyclin based inhibitors of cdk2 and cdk4: Structural and functional analysis of peptide inhibitor binding to the cyclin D and cyclin A groove has been investigated and used to design peptides that provide the basis for structure-activity relationships, have improved binding and have potential for development as chemical biology probes, as potential diagnostics and as therapeutics in... Agent:

20150011731 - Dye compositions, methods of preparation, conjugates thereof, and methods of use: Dye compounds of the formula (1) wherein A is a protective agent group that has a characteristic of modifying the singlet-triplet occupancy of the shown cyanine moiety, and M is a reactive crosslinking group or a group that can be converted to a reactive crosslinking group. Methods for synthesizing the... Agent: Cornell University

20150011732 - Polymer conjugates of interferon beta-1a and uses: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as... Agent:

20150011733 - Collagen 7 and related methods: Disclosed are methods of making collagen 7, or functional fragments thereof, as well as collagen 7, and functional fragments thereof produced by such methods, nucleic acids encoding collagen 7, and functional fragments thereof, as well as vectors and host cells comprising such nucleic acids.... Agent:

20150011734 - Protein and gene related with basal thermotolerance of plants: An isolated protein having SEQ ID NO:1 and an isolated gene encoding the protein are provided. The protein is related with basal thermotolerance of plants having the protein.... Agent: National Central University

20150011735 - Apolipoprotein l-i variants and their use: The present invention is related to an isolated human Apolipoprotein L-I corresponding to this wild type human Apolipoprotein sequence modified by a deletion at its C-terminal end.... Agent:

20150011736 - Binding molecule conjugates: The present invention concerns methods for identifying, producing, and engineering binding molecule conjugates, and to the conjugates produced. In particular, the invention concerns Surrobody conjugates composed of an antibody heavy chain variable domain and a surrogate light chain, wherein the surrogate light chain and/or the antibody heavy chain variable domain... Agent:

20150011737 - Tailorable lignosulfonate carbonate adhesives: A two component adhesive system is described. The first component of the system is made from a sulfonated lignin having at least one amine group containing side arm and at least one hydroxyl group containing side arm. The second component of the system is made from a sulfonated lignin having... Agent:

01/01/2015 > 12 patent applications in 10 patent subcategories.

20150005471 - Assays for detecting modified compounds: Provided are methods and compositions which are useful for separating, isolating, detecting, and quantifying compounds of interest which have been modified chemically, enzymatically or catalytically from other compounds which have not been so modified. The modifications may take the form of functional groups which are gained, lost or retained by... Agent: Enzo Life Sciences, Inc. C/o Enzo Biochem, Inc.

20150005472 - Method for producing milk protein fibres: The disclosure relates to milk protein micro and super-micro fibres (MPM) and polymer nano fibres (MPN) produced according to a spinning method, in which at least one protein, which is obtained from milk and which can be thermally plasticized, is plasticized using a plasticizing agent, such as for example, water... Agent:

20150005473 - Recombinant expression vector system for variants of coagulation factor viii and von willebrand factor: Disclosed is an expression vector system for variants of coagulation Factor VIII (FVIII) and von Willebrand Factor (vWF). In detail, mutant vWF the size of which is significantly reduced by deleting exons but which has remarkably increased FVIII stabilizing and activating efficiency, and an expression vector system useful for the... Agent: Korea University Industrial & Academic Collaborative Foundation

20150005474 - Recognition molecules for the treatment and detection of tumors: The invention relates to recognition molecules directed towards tumors, and it also relates to pharmaceutical compositions comprising said recognition molecules, methods for the production of said recognition molecules, and to the use of said recognition molecules in the diagnosis and therapy of tumor diseases.... Agent:

20150005475 - Process for reducing antibody aggregate levels and antibodies produced thereby: The disclosure provides a method of reducing aggregates in a preparation of monoclonal antibody by modifying at least three parameters in the bioreactor culture process.... Agent: Medimmune Limited

20150005476 - Process for enriching iga: The invention relates to a process for enriching IgA (and IgM) from IgA-comprising material. In particular, it relates to a sequential elution process of an anion exchanger that leads to an advantageous enrichment and separation of monomeric and dimeric IgA.... Agent: Csl Behring Ag

20150005477 - Compositions and methods for conjugating activatable antibodies: The invention relates generally to compositions and methods for conjugating antibodies and activatable antibodies, and methods of partially reducing antibodies and/or activatable antibodies prior to conjugation, e.g., thiol-based conjugation, with an agent, e.g., a therapeutic and/or diagnostic agent.... Agent:

20150005479 - Bioprocessing device: Provided is a bioprocessing device including a hybrid of (1) a protein having a redox potential; and (b) a single strand DNA (ssDNA) conjugated to the protein. The bioprocessing device of the present invention has a function of information reinforcement, information regulation, or information amplification. This bioprocessing device of the... Agent: Industry-university Cooperation Foundation Sogang University

20150005478 - Method for purifying lactoferrin: The present invention relates to a method for purifying lactoferrin, which is a pharmacologically important milk protein having various physiological activities, from a secretory fluid containing lactoferrin.... Agent:

20150005480 - Affinity tag system: The present invention pertains to an affinity tag system for the immobilisation and/or purification of molecules such as biological or organic molecules. The invention provides EF-hand subdomains of calcium binding proteins, such as calbindin D9k, as affinity tags and affinity ligands for immobilising, detecting and/or for purifying molecules, particularly proteins.... Agent: University College Dublin

20150005481 - Norbornene modified peptides and their labelling with tetrazine compounds: The invention relates to a polypeptide comprising an amino acid having a norbornene group. Suitably said norbornene group is present as an amino acid residue of a norbornene lysine. The invention also relates to a method of producing a polypeptide comprising a norbornene group, said method comprising genetically incorporating an... Agent: North Carlolina State University

20150005482 - Separation of biocomponents from manure: A process for separating amino acids and peptides from raw and digested farm manure is disclosed. The raw manure may be recovered from sand bedding used in the cow stalls of some farms. The process involves the steps of precipitating out struvite and separating a stream rich in amino acids... Agent:

12/25/2014 > 20 patent applications in 12 patent subcategories.

20140378652 - Method for preparing multiple antigen glycopeptide carbohydrate conjugates: The present invention relates to a method for preparing carbohydrate T cell epitope conjugates of formula (I): M(T-B)n(I) wherein M, T, B and n are as defined in claim 1.... Agent: Institut Pasteur

20140378653 - Factor xii inhibitors for the treatment of neurological inflammatory disorders: This application relates to neurological inflammatory diseases, such as multiple sclerosis, and to methods of administering a Factor XII inhibitor to prevent, treat, or otherwise ameliorate the effects of a neurological inflammatory disease, such as multiple sclerosis. Agents and pharmaceutical compositions comprising agents which inhibit the activity of FXII are... Agent:

20140378654 - Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors: The present invention provides methods of specifically targeting compounds to cells overexpressing matrix metalloproteinases, plasminogen activators, or plasminogen activator receptors, by administering a compound and a mutant protective antigen protein comprising a matrix metalloproteinase or a plasminogen activator-recognized cleavage site in place of the native protective antigen furin-recognized cleavage site,... Agent:

20140378655 - Stabilized formulations of peptides and proteins: Stabilization of water-containing solutions or lyophilizates of proteins and peptide against non-enzymatic deamidation degradation reactions at asparaginyl or glutaminyhl residues is achieved using organic anions, such as saccharin, benzenesulfonic acid, gentisic acide or N-acetyltryptophan which have a pKa within the range of 0.5 to 3.5... Agent:

20140378660 - Mirac proteins: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.... Agent: Bioatla LLC

20140378658 - Neurological therapies: Cytotoxic necrotising factor 1 (CNF1) treats dysfunctional astrocytes and is useful to treat conditions associated with astrogliosis and/or neuroinflammation.... Agent: Alma Mater Studiorum-universita Di Bologna

20140378659 - Oxidized ldl inhibitor: The present invention provides an oxidized LDL inhibitor that is capable of (i) binding specifically to oxidized LDL, (ii) suppressing the physiological activity of oxidized LDL, and (iii) inhibiting the uptake of oxidized LDL into cells. The oxidized LDL inhibitor according to the present invention contains a Del-1 protein as... Agent:

20140378656 - Soluble tcr molecules and methods of use: Disclosed are compositions and methods for detecting cells or tissue comprising a peptide antigen presented in the context of an MHC or HLA complex. The invention has a wide range of applications including providing a highly sensitive method for detecting cancer cells.... Agent: Altor Bioscience Corporation

20140378657 - Streptavidin mutein exhibiting reversible binding for biotin and streptavidin binding peptide tagged proteins: The present invention relates to a new streptavidin muteins. This mutein is binds both streptavidin binding peptide tagged and biotin or biotinylated molecules, and does so in a reversible fashion. As such, it is stable enough to allow reuse, and producible with reasonable production yield via secretion in a soluble... Agent: Uti Limited Partnership

20140378661 - Molded regenerated silk geometries using temperature control and mechanical processing: The present disclosure provides methods for fabricating various regenerated silk geometries using temperature control. In addition to temperature control, mechanical processing can be used to enhance properties of the fabricated article. The present disclosure also provides silk foam and paper-like materials molded using freezer processing.... Agent: Trustees Of Tufts College

20140378662 - Method for producing tissue repair material: A method of producing a tissue repair material, the method including: (a) obtaining a gelatin-containing intermediate that contains a gelatin and has a mesh structure, using a gelatin solution in which the gelatin is dissolved in an aqueous medium; (b) drying the gelatin-containing intermediate; and (c) cross-linking the gelatin before... Agent: Fujifilm Corporation

20140378666 - Dual specificity antibodies and methods of making and using: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1α and IL-1β and neutralize IL-1α and IL-1β activity in vitro and in vivo. An antibody of... Agent: Abbvie Inc.

20140378663 - Fc variants with reduced effector functions: A method for producing a variant of a parent polypeptide including a Fc region, which variant exhibits reduced binding to the protein C1q and to at least one receptor Fcgγ R as compared to the parent polypeptide.... Agent: Laboratoire Francais Du Fractionnement Et De Biotechnologies

20140378665 - Growth differentiation factor 15 (gdf-15) polypeptides: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose... Agent:

20140378664 - Protein complex, bispecific antibody including the protein complex, and method of preparation thereof: a linker connecting the first polypeptide and the second polypeptide, wherein the first antigen-binding region is a single stranded polypeptide comprising a first light chain antigen-binding region and a first heavy chain antigen-binding region, the second antigen-binding region is a single stranded polypeptide comprising a second light chain antigen-binding region... Agent:

20140378667 - Transgenic plants modified for reduced cadmium transport, derivative products, and related methods: Various embodiments are directed to transgenic plants, including transgenic tobacco plants and derivative seeds, genetically modified to impede the transport of Cadmium (Cd) from the root system to aerial portions of transgenic plants by reducing the expression levels of HMA-related transporters. Various embodiments are directed to transgenic tobacco plants genetically... Agent:

20140378668 - Tyrosine bioconjugation through aqueous ene-like reactions: A new and versatile class of cyclic diazodicarboxamides that reacts efficiently and selectively with phenols and the phenolic side chain of tyrosine through an Ene-like reaction is reported. This mild aqueous tyrosine ligation reaction works over a broad pH range and expands the repertoire of aqueous chemistries available for small... Agent:

20140378669 - Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-d-manno-octulsonic acid: Methods for preparing an oligosaccharide—protein carrier immunogenic conjugate or a polysaccharide—protein carrier immunogenic conjugate. The methods include obtaining an oligosaccharide or polysaccharide having a KDO moiety located at the terminal reducing end of the oligosaccharide or polysaccharide that includes a carbonyl functional group; and reacting the carbonyl functional group of... Agent: National Research Council Of Canada

20140378670 - Immobilized proteins and methods and uses thereof: The invention relates to the field of covalently attaching proteins to a substrate, particularly to methods of immobilizing proteins by posttranslationally modifying a cysteine residue of said protein through the addition of functional groups. The invention also relates to biological molecules used in such techniques, including proteins, and detection methods... Agent:

20140378671 - Phosphonate-substituted lignin as a flame retardant: Modified lignin having covalently attached phosphorous containing groups and methods for preparing such compounds are described herein. The modified lignin described herein provides a renewable source of flame retardant material.... Agent:

Previous industry: Synthetic resins or natural rubbers -- part of the class 520 series
Next industry: Organic compounds -- part of the class -570 series


RSS FEED for 20150115: xml
Integrate into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.


Thank you for viewing Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents on the website. These are patent applications which have been filed in the United States. There are a variety ways to browse Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents we recommend signing up for free keyword monitoring by email.

Results in 0.48897 seconds